Carter Gould Analyst Performance

Biopharma Equity Research at Cantor Fitzgerald

Carter Gould is a stock analyst at Cantor Fitzgerald focused in the medical sector, covering 20 publicly traded companies. Over the past year, Carter Gould has issued 13 stock ratings, including buy and hold recommendations. While full access to Carter Gould's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Carter Gould's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

59 Last 8 Years

Buy Recommendations

52.08% 25 Buy Ratings

Companies Covered

20 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	52.1%	25 ratings
Hold	41.7%	20 ratings
Sell	6.3%	3 ratings

Out of 48 total stock ratings issued by Carter Gould at Cantor Fitzgerald, the majority (52.1%) have been Buy recommendations, followed by 41.7% Hold and 6.3% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  AVXS

  Jan 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  CNCE

  Nov 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	70.0% of companies on NASDAQ	14 companies
NYSE	30.0% of companies on NYSE	6 companies

Carter Gould, an analyst at Cantor Fitzgerald, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 19 companies	95.0%
	Computer and Technology 1 company	5.0%

Carter Gould of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 10 companies	50.0%
LARGE CAP PHARMA 4 companies	20.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 2 companies	10.0%
COMP - SOFTWARE 1 company	5.0%
PHARMACEUTICAL PREPARATIONS 1 company	5.0%
BIOTECHNOLOGY 1 company	5.0%
MED - DRUGS 1 company	5.0%

Carter Gould's Ratings History at Cantor Fitzgerald

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
ABBV AbbVie	9/15/2025	Boost Price Target	$218.40	$245.00	Overweight	$0.00 00.00% ROI
LLY Eli Lilly and Company	8/13/2025	Lower Price Target	$659.89	$825.00	Overweight	$0.00 00.00% ROI
VRTX Vertex Pharmaceuticals	8/5/2025	Lower Price Target	$472.27	$485.00	Overweight	$0.00 00.00% ROI
CRM Salesforce	4/23/2025	Initiated Coverage	$255.39	$210.00	Overweight	$0.00 00.00% ROI
REGN Regeneron Pharmaceuticals	4/22/2025	Initiated Coverage	$561.49	$695.00	Overweight	$0.00 00.00% ROI
GILD Gilead Sciences	4/22/2025	Initiated Coverage	$104.33	$125.00	Overweight	$0.00 00.00% ROI
LLY Eli Lilly and Company	4/22/2025	Initiated Coverage	$818.18	$975.00	Overweight	$0.00 00.00% ROI
VRTX Vertex Pharmaceuticals	4/22/2025	Reiterated Rating	$477.52	$535.00	Overweight	$0.00 00.00% ROI
PFE Pfizer	4/22/2025	Initiated Coverage	$22.07	$24.00	Neutral	$0.00 00.00% ROI
PCVX Vaxcyte	4/22/2025	Initiated Coverage	$30.39		Overweight	$0.00 00.00% ROI
MRK Merck & Co., Inc.	4/22/2025	Initiated Coverage	$77.91	$85.00	Neutral	$0.00 00.00% ROI
BMY Bristol Myers Squibb	4/22/2025	Reiterated Rating	$48.95	$55.00	Neutral	$0.00 00.00% ROI
ABBV AbbVie	4/22/2025	Initiated Coverage	$170.01	$210.00	Overweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.